TABLE 1. TOTAL COMMITTED PUBLIC FUNDING FOR ANTIBACTERIAL RESISTANCE RESEARCH BY JPIAMR COUNTRIES
TABLE 2. RECOMMENDED DOSAGE SCHEDULE FOR CEFTAZIMIDE
TABLE 3. CEFTAZIMIDE MARKET VALUE, 2016-2023 ($MILLION)
TABLE 4. AVERAGE SELLING PRICE ($) OF CEFTAZIMIDE
TABLE 5. RECOMMENDED DOSAGE SCHEDULE FOR CEFTIN
TABLE 6. CEFUROXIME MARKET VALUE, 2016-2023 ($MILLION)
TABLE 7. AVERAGE SELLING PRICE ($) OF CEFUROXIME
TABLE 8. NONCLASSIFIED AND COMBINATION CEPHALOSPORINS
TABLE 9. GLOBAL CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 10. FIRST-GENERATION CEPHALOSPORINS
TABLE 11. FIRST-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 12. SECOND-GENERATION CEPHALOSPORINS
TABLE 13. SECOND-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 14. THIRD-GENERATION CEPHALOSPORINS
TABLE 15. THIRD-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 16. FOURTH-GENERATION CEPHALOSPORINS
TABLE 17. FOURTH-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 18. FIFTH-GENERATION CEPHALOSPORINS
TABLE 19. FIFTH-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GLOBAL CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 21. BRANDED CEPHALOSPORIN DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 22. GENERIC CEPHALOSPORIN DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 23. GLOBAL CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 24. CEPHALOSPORIN DRUGS THAT ARE GIVEN AS INJECTION
TABLE 25. CEPHALOSPORIN INJECTIONS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 26. ORAL CEPHALOSPORIN DRUGS
TABLE 27. ORAL CEPHALOSPORIN DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 28. GLOBAL CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 29. CEPHALOSPORIN DRUGS USED TO TREAT RESPIRATORY TRACT INFECTION
TABLE 30. CEPHALOSPORIN MARKET FOR RESPIRATORY TRACT INFECTION, BY REGION, 2016-2023 ($MILLION)
TABLE 31. CEPHALOSPORIN DRUGS USED TO TREAT SKIN INFECTION
TABLE 32. CEPHALOSPORIN MARKET FOR SKIN INFECTION, BY REGION, 2016-2023 ($MILLION)
TABLE 33. CEPHALOSPORIN DRUGS USED TO TREAT EAR INFECTION
TABLE 34. CEPHALOSPORIN MARKET FOR EAR INFECTION, BY REGION, 2016-2023 ($MILLION)
TABLE 35. CEPHALOSPORIN DRUGS USED TO TREAT URINARY TRACT INFECTION
TABLE 36. CEPHALOSPORIN MARKET FOR URINARY TRACT INFECTION, BY REGION, 2016-2023 ($MILLION)
TABLE 37. CEPHALOSPORIN DRUGS USED TO TREAT INFECTION CAUSED DUE TO GONORRHOEA
TABLE 38. CEPHALOSPORIN MARKET FOR SEXUALLY TRANSMITTED INFECTION, BY REGION, 2016-2023 ($MILLION)
TABLE 39. CEPHALOSPORIN DRUGS USED FOR OTHER APPLICATIONS
TABLE 40. CEPHALOSPORIN MARKET FOR OTHER APPLICATIONS, BY REGION, 2016-2023 ($MILLION)
TABLE 41. GLOBAL CEPHALOSPORIN MARKET, BY REGION ($MILLION), 2016-2023
TABLE 42. NORTH AMERICA CEPHALOSPORIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 43. U.S. CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 44. U.S. CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 45. U.S. CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 46. U.S. CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 47. CANADA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 48. CANADA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 49. CANADA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 50. CANADA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 51. MEXICO CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 52. MEXICO CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 53. MEXICO CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 54. MEXICO CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 55. NORTH AMERICA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 56. NORTH AMERICA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 57. NORTH AMERICA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 58. NORTH AMERICA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 59. TOP FIVE EUROPEAN COUNTRIES PER STI, 2000-2013
TABLE 60. EUROPE CEPHALOSPORIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 61. GERMANY CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 62. GERMANY CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 63. GERMANY CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 64. GERMANY CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 65. FRANCE CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 66. FRANCE CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 67. FRANCE CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 68. FRANCE CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 69. UK CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 70. UK CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 71. UK CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 72. UK CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 73. ITALY CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 74. ITALY CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 75. ITALY CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 76. ITALY CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 77. SPAIN CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 78. SPAIN CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 79. SPAIN CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 80. SPAIN CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 81. REST OF EUROPE CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 82. REST OF EUROPE CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 83. REST OF EUROPE CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 84. REST OF EUROPE CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 85. EUROPE CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 86. EUROPE CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 87. EUROPE CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 88. EUROPE CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 89. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 90. JAPAN CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 91. JAPAN CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 92. JAPAN CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 93. JAPAN CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 94. CHINA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 95. CHINA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 96. CHINA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 97. CHINA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 98. INDIA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 99. INDIA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 100. INDIA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 101. INDIA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 102. AUSTRALIA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 103. AUSTRALIA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 104. AUSTRALIA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 105. AUSTRALIA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 106. SOUTH KOREA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 107. SOUTH KOREA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 108. SOUTH KOREA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 109. SOUTH KOREA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 110. REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 111. REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 112. REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 113. REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 114. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 115. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 116. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 117. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 118. LAMEA CEPHALOSPORIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 119. BRAZIL CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 120. BRAZIL CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 121. BRAZIL CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 122. BRAZIL CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 123. SOUTH AFRICA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 124. SOUTH AFRICA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 125. SOUTH AFRICA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 126. SOUTH AFRICA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 127. SAUDI ARABIA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 128. SAUDI ARABIA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 129. SAUDI ARABIA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 130. SAUDI ARABIA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 131. REST OF LAMEA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 132. REST OF LAMEA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 133. REST OF LAMEA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 134. REST OF LAMEA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 135. LAMEA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 136. LAMEA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 137. LAMEA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 138. LAMEA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 139. ALLERGAN: COMPANY SNAPSHOT
TABLE 140. ALLERGEN: OPERATING SEGMENTS
TABLE 141. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 142. BRISTOL-MYERS SQUIBB: PRODUCT SEGMENTS
TABLE 143. LILLY: COMPANY SNAPSHOT
TABLE 144. LILLY OPERATING SEGMENTS
TABLE 145. ROCHE: COMPANY SNAPSHOT
TABLE 146. ROCHE: OPERATING SEGMENTS
TABLE 147. GSK: COMPANY SNAPSHOT
TABLE 148. GSK: OPERATING SEGMENTS
TABLE 149. LUPIN LIMITED: COMPANY SNAPSHOT
TABLE 150. LUPIN LIMITED: OPERATING SEGMENTS
TABLE 151. MERCK: COMPANY SNAPSHOT
TABLE 152. MERCK: OPERATING SEGMENTS
TABLE 153. PFIZER: COMPANY SNAPSHOT
TABLE 154. PFIZER: OPERATING SEGMENTS
TABLE 155. SANOFI: COMPANY SNAPSHOT
TABLE 156. SANOFI: OPERATING SEGMENTS
TABLE 157. TEVA: COMPANY SNAPSHOT
TABLE 158. TEVA: OPERATING SEGMENTS

LIST OF FIGURE

FIGURE 1. CEPHALOSPORIN MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP WINNING STRATEGIES, 2015-2017 (%)
FIGURE 4. TOP COMPANIES AND THEIR STRATEGIES, 2015-2017
FIGURE 5. MARKET SHARE ANALYSIS, 2016
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF SUBSTITUTION
FIGURE 9. THREAT OF NEW ENTRANT
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. AGEADJUSTED DEATH RATES CAUSED DUE TO PNEUMONIA IN THE U.S., BY SEX, 2013
FIGURE 12. AGEADJUSTED DEATH RATES CAUSED DUE TO PNEUMONIA IN THE U.S., BY AGE GROUP, 2013
FIGURE 13. ALLERGAN: REVENUE, 2014-2016 ($MILLION)
FIGURE 14. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 15. BRISTOL-MYERS SQUIBB: REVENUE, 2014-2016 ($MILLION)
FIGURE 16. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY PRODUCT, 2016 (%)
FIGURE 17. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 18. LILLY: REVENUE, 2014-2016 ($MILLION)
FIGURE 19. LILLY: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 20. LILLY: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 21. ROCHE: NET SALES, 2014-2016 ($MILLION)
FIGURE 22. ROCHE: NET SALES BY SEGMENT, 2016 (%)
FIGURE 23. ROCHE: NET SALES BY GEOGRAPHY, 2016 (%)
FIGURE 24. GSK: REVENUE, 2014-2016 ($MILLION)
FIGURE 25. GSK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 26. GSK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 27. LUPIN LIMITED: NET SALES, 2014-2016 ($MILLION)
FIGURE 28. LUPIN LIMITED: NET SALES BY GEOGRAPHY, 2016 (%)
FIGURE 29. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 30. MERCK: NET SALES BY SEGMENT, 2016 (%)
FIGURE 31. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 32. PFIZER: REVENUE, 2014-2016 ($MILLION)
FIGURE 33. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 34. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 35. SANOFI: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. SANOFI: NET SALES BY SEGMENT, 2016 (%)
FIGURE 37. SANOFI: NET SALES BY GEOGRAPHY, 2016 (%)
FIGURE 38. TEVA: REVENUE, 2014-2016 ($MILLION)
FIGURE 39. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 40. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)